MX2022011676A - Proteinas de fusion de il12 con enmascaramiento y metodos para su uso. - Google Patents

Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.

Info

Publication number
MX2022011676A
MX2022011676A MX2022011676A MX2022011676A MX2022011676A MX 2022011676 A MX2022011676 A MX 2022011676A MX 2022011676 A MX2022011676 A MX 2022011676A MX 2022011676 A MX2022011676 A MX 2022011676A MX 2022011676 A MX2022011676 A MX 2022011676A
Authority
MX
Mexico
Prior art keywords
masked
methods
fusion proteins
compositions
variety
Prior art date
Application number
MX2022011676A
Other languages
English (en)
Spanish (es)
Inventor
Von Kreudenstein Thomas Spreter
Gesa Volkers
Nicole Afacan
Genevieve Desjardins
David Douda
Ryan Blackler
Original Assignee
Zymeworks Bc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Bc Inc filed Critical Zymeworks Bc Inc
Publication of MX2022011676A publication Critical patent/MX2022011676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2022011676A 2020-03-23 2021-03-23 Proteinas de fusion de il12 con enmascaramiento y metodos para su uso. MX2022011676A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993334P 2020-03-23 2020-03-23
US202163146567P 2021-02-05 2021-02-05
PCT/CA2021/050383 WO2021189139A1 (en) 2020-03-23 2021-03-23 Masked il12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022011676A true MX2022011676A (es) 2023-03-08

Family

ID=77890776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011676A MX2022011676A (es) 2020-03-23 2021-03-23 Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.

Country Status (10)

Country Link
US (1) US20230122079A1 (https=)
EP (1) EP4126972A4 (https=)
JP (1) JP7773991B2 (https=)
KR (1) KR20230024252A (https=)
CN (1) CN115529826A (https=)
AU (1) AU2021240872A1 (https=)
BR (1) BR112022019020A2 (https=)
CA (1) CA3147126A1 (https=)
MX (1) MX2022011676A (https=)
WO (1) WO2021189139A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CA3178657A1 (en) * 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
WO2022155263A2 (en) * 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023050006A1 (en) * 2021-09-29 2023-04-06 Zymeworks Bc Inc. Modified interleukin p40 subunit proteins and methods of use thereof
EP4466290A4 (en) * 2022-01-20 2026-02-11 Repertoire Immune Medicines Inc IL-12 FUSION PROTEINS TARGETING CD8
US20250114489A1 (en) * 2022-02-15 2025-04-10 Tagworks Pharmaceuticals B.V. Masked il12 protein
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2024148369A1 (en) * 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
IL322055A (en) * 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
EP4704979A1 (en) * 2023-01-20 2026-03-11 Boehringer Ingelheim International GmbH Il-12 fc fusion proteins
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥（香港）有限公司 Ｋｌｋ１融合蛋白質的製備方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN119823266A (zh) * 2023-10-13 2025-04-15 英脉德医疗科技(广东)有限公司 肿瘤微环境特异激活的cd47抗体
TW202523680A (zh) * 2023-12-07 2025-06-16 大陸商上海藥明生物技術有限公司 針對ｉｌ－１２受體的異二聚體蛋白
WO2025122957A1 (en) * 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
CN117838836B (zh) * 2024-01-11 2024-06-28 广州医科大学附属第二医院 白介素39在防治血小板减少症中的应用
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019288484B2 (en) * 2018-06-22 2024-06-20 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
WO2020160189A1 (en) * 2019-01-29 2020-08-06 Gritstone Oncology, Inc. Multispecific binding proteins
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN110777115B (zh) 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
WO2022016270A1 (en) * 2020-07-20 2022-01-27 Zymeworks Inc. Fusion proteins comprising a ligand-receptor pair and a biologically functional protein

Also Published As

Publication number Publication date
JP7773991B2 (ja) 2025-11-20
US20230122079A1 (en) 2023-04-20
BR112022019020A2 (pt) 2023-02-07
JP2023518518A (ja) 2023-05-01
AU2021240872A1 (en) 2022-11-17
EP4126972A4 (en) 2024-05-01
CA3147126A1 (en) 2021-09-30
KR20230024252A (ko) 2023-02-20
CN115529826A (zh) 2022-12-27
WO2021189139A1 (en) 2021-09-30
EP4126972A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
EP4620531A3 (en) Bicyclic heteroaryl compounds and uses thereof
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MY199968A (en) Formulations of an lsd1 inhibitor
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
WO2022038417A3 (en) Modified il-18 polypeptides and uses thereof
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
SA523440623B1 (ar) أجسام مضادة
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
MY209833A (en) Elacestrant in combination with abemaciclib in women with breast cancer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
PH12022552710A1 (en) Anti-flt3 antibodies and compositions
SE0300098D0 (sv) Use of cyclin D1 inhibitors
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
EP4512816A3 (en) Tlr7 agonists